Home > List All Publishers > Decision Resources

Decision Resources

For almost three decades, Decision Resources has provided in-depth research on the trends, emerging developments, and market potential of the drug industry. Large pharmaceutical companies as well as startup biotechs turn to Decision Resources for the information they need to license, market, and compete. The privately owned company offers research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets. Using both primary and secondary resources, their highly credentialed in-house staff studies surveys and data, and conduct interviews with physicians to determine the status of a variety of diseases and drugs. By assessing international pharmaceutical and health care industry trends, Decision Resources can present specific conclusions that help organizations achieve commercial success.

List of reports from Decision Resources

Breast Cancer in Mexico 11/30/2012 \| published by: Decision Resources ... United Kingdom, and Japan). This growing incident population and the launches of several novel high-value agents will be the key drivers of market growth for CaB in Mexico through 2016. Mexico’s lack of legal requirement ... \| read more...	$15,000.00
LaunchTrends®: Abatacept SC (Orencia SC) (Wave 4) 2012 11/30/2012 \| published by: Decision Resources ... trial, adoption and usage of new products at one month, three months, six months and one year post launch. These report series provide information on how new products fit into the treatment algorithm, impact current ... \| read more...	$15,000.00
Niche Markets and Rare Diseases: Amyotrophic Lateral Sclerosis 11/30/2012 \| published by: Decision Resources ... of patients die within 30 months of symptom onset and only one-fifth survive beyond five years after symptom onset. At present, just one therapy is approved for the treatment of ALS, riluzole (Sanofi’s Rilutek), a ... \| read more...	$10,000.00
Niche Markets and Rare Diseases: Graft Versus Host Disease 11/30/2012 \| published by: Decision Resources ... prevent and poorly responsive to current treatments—presents opportunities for drug developers. Physicians are particularly dissatisfied with therapeutic options for treatment-refractory GVHD and are already willing to use almost any drug supported by a reasonable mechanistic ... \| read more...	$10,000.00
Novel Injectable Therapies for Type 2 Diabetes: What U.S. Market Access Hurdles Will Novel GLP-1 Receptor Agonists and Next-Generation Insulin Therapies Have to Clear? Physician and Payer Insights 11/30/2012 \| published by: Decision Resources ... PCPs, and 25 pharmacy/medical directors at MCOs that offer both commercial health insurance and Medicare Part D plans. The United States type 2 diabetes market continues to grow due to increases in the prevalent population ... \| read more...	$10,000.00
Rheumatoid Arthritis in Brazil, Russia, and China – How Are Payers and Prescribers Promoting or Limiting Growth in the Biologics Markets 11/30/2012 \| published by: Decision Resources ... by a growing prevalent population with greater access to medical care and by rheumatologists’ increasing use of more aggressive treatments. Increased government spending on healthcare and improved penetration of biological agents make this an attractive ... \| read more...	$10,000.00
TreatmentTrends®: Advanced/Metastatic Breast Cancer (US) 2012 11/30/2012 \| published by: Decision Resources ... provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players. Please ... \| read more...	$15,000.00
Italy: Market Access Tracker 11/29/2012 \| published by: Decision Resources ... years ($16.2 billion in 2011) and is steadily sliding down the global rankings. The relative decline of the Italian market reflects the government’s increasingly stringent cost-containment strategy. Faced with crippling debt, the Italian government has ... \| read more...	$4,000.00
Turkey: Market Access Tracker 11/29/2012 \| published by: Decision Resources ... a universal health insurance system have boosted demand for healthcare services, including prescription drugs. However, a tough pricing and reimbursement environment and restrictions on market access for new imported drugs present serious challenges for multinational ... \| read more...	$4,000.00
Oncology Patient Flow Model: Ovarian Cancer 11/28/2012 \| published by: Decision Resources ... a 20 year forecast period in a data rich, graphical and interactive environment with Pharmacor Patient Flow Models. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
TreatmentTrends®: Multiple Sclerosis (EU) 2012 11/28/2012 \| published by: Decision Resources ... practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key market players. Please note, the PDF ... \| read more...	$15,000.00
ChartTrends®: Lupus (US) 2012 11/27/2012 \| published by: Decision Resources ... syndicated reports designed to compare what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, ... \| read more...	$15,000.00
Atrial Fibrillation in Brazil 11/26/2012 \| published by: Decision Resources ... its main complication: stroke. Furthermore, the opportunity for novel therapies that reduce stroke and agents that can maintain regular heart rhythm is expanding because of an aging population and growing awareness of the limitations of ... \| read more...	$15,000.00
Market Access Obstacles in the European Gout Market: Physician and Payer Perspectives on Opportunities for Novel Acute and Chronic Gout Therapies 11/26/2012 \| published by: Decision Resources ... position present a formidable barrier to the uptake of more expensive alternatives such as The Menarini Group/Ipsen’s Adenuric (febuxostat), despite the latter agent’s superior clinical profile. However, although the gout market access barrier is set ... \| read more...	$15,000.00
Gout 11/26/2012 \| published by: Decision Resources ... Kingdom, and Japan); we expect the diagnosed prevalence to increase to 17.7 million by 2021. The residual unmet need in gout centers on patients who cannot control their serum uric acid (sUA) with the widely ... \| read more...	$15,000.00
Ovarian Cancer 11/26/2012 \| published by: Decision Resources ... therapy to be approved in this market, at the end of 2011, was bevacizumab (Roche/Genentech/Chugai’s Avastin), and with the agent set to penetrate several market segments, a need remains for novel therapies to diversify treatment ... \| read more...	$15,000.00
LaunchTrends®: Enzalutimide (Xtandi) (Wave 1) US 2012 11/26/2012 \| published by: Decision Resources ... track the uptake of Xtandi at 1 month, 6 months, and 1 year following product availability in the United States. LaunchTrends® are syndicated reports that track the trial, adoption and usage of new products from ... \| read more...	$15,000.00
Hospital-Treated Infections 11/26/2012 \| published by: Decision Resources ... of their severity and the higher prevalence of antimicrobial resistance. However, this market is already served by numerous antibiotics from diverse drug classes, most of them generically available, and generics competition will intensify as several ... \| read more...	$15,000.00
Innovative R&D and Dealmaking Opportunities: Oncology - Novel Targeted Small-Molecule Therapies 11/21/2012 \| published by: Decision Resources ... shifted cancer treatment paradigms, and many targeted agents have achieved blockbuster status, led by Novartis’s Gleevec (imatinib). Targeted therapies for a range of solid and hematological cancers are now widely prescribed. Efforts to develop novel ... \| read more...	$10,000.00
Venous Thromboembolism 11/19/2012 \| published by: Decision Resources ... more-convenient alternatives to current standards of care in certain VTE populations, and these agents will drive market expansion from 2011 to 2021. However, opportunities remain in still-underserved VTE indications, including primary prophylaxis of VTE in ... \| read more...	$15,000.00
Oncology Patient Flow Model: Non-Small-Cell Lung Cancer 11/16/2012 \| published by: Decision Resources ... a 20 year forecast period in a data rich, graphical and interactive environment with Pharmacor Patient Flow Models. Please note, the PDF e-mail from publisher version of this report is for a global site license. \| read more...	$15,000.00
Chemotherapy-Induced Nausea and Vomiting: How Are Payers, Prescribers, and Oncology Nurses Shaping This Buoyant Market? 11/16/2012 \| published by: Decision Resources ... for maintaining optimal cancer therapy and achieving the best possible clinical outcome. The CINV drug therapy arena is dominated by three major drug classes; serotonin (5HT 3 ) receptor antagonists (RAs), neurokinin (NK 1 ) ... \| read more...	$10,000.00
How Will the Launches of Oral Immunomodulators and Biosimilars Shape the EU5 Prescribing and Reimbursement Landscape for Current and Emerging Biologics in Rheumatoid Arthritis? 11/16/2012 \| published by: Decision Resources ... include five tumor necrosis factor-alpha (TNF-a) inhibitors, Bristol-Myers Squibb’s selective costimulation modulator Orencia, Roche’s MabThera (Roche/Biogen Idec Chugai/Zenyaku Kogyo’s B-cell inhibitor Rituxan), and the more recently launched interleukin-6 (IL-6) inhibitor Actemra/RoActemra from Roche/Chugai. However, two ... \| read more...	$10,000.00
TreatmentTrends®: Non-Small-Cell Lung Cancer (EU) 2012 11/16/2012 \| published by: Decision Resources ... market dynamics. They provide insight into practice patterns, attitudes and perceptions, and current and projected use of various products. TreatmentTrends® evaluate perceived product advantages and disadvantages, as well as sales and messaging efforts of key ... \| read more...	$15,000.00
Europe: Market Access Tracker 11/14/2012 \| published by: Decision Resources ... the United Kingdom. Timely analysis of key events, regular webinar update presentations, and access to our team of experts will equip biopharmaceutical companies with the insight needed to evaluate the implications of the latest changes ... \| read more...	$4,000.00

< prev 1 2 3 4 5 6 7 8 9 10 next >